Accessing New Drugs Perspective from Pharma Raphaël Rousseau, MD, PhD Assoc. Group Medical Director Global Development Team Leader, Pediatric Oncology Drug Development Program Genentech, a member of the Roche group South San Francisco, USA Disclaimer Some comments & views expressed in this presentation are mine and not necessarily shared by Roche, Genentech or affiliated parties A pediatrician’s atypical journey from bench to bedside… to the pharmaceutical industry identify pathways “cure cancer in mice” move to the clinic < proof-of-concept preclinical sometimes up to phase 1 = funding translational challenges focus on one disease obtain drugs from Pharma collaborate with peers generate a portfolio strategy explore multiple diseases collaborate w/ Academia, Regulators, Parent at best < confirmatory phase 1, 2 trials < safety and efficacy phase 3 registration if positive = challenging timelines costs attrition rate access to patients rarely phase 3 to industry’s portfolio = access resources for clinical research beyond clinical research: registration Symposium 2 – Saturday 13:50-15:20 - CARs on track in the clinic: are chimeric artificial receptors a true novel perspective for the cure of resistant childhood leukaemias? The complexity of industry workflows integrating therapeutic & diagnostic R&Ds without delaying either of the processes compliance check(s) Rx R&D process and decision points Development ~8yrs Research ~7yrs New Medicines Proposal Target Validatio n Lead Identificatio n Lead Optimisation Project Initiation EIH Enabling Phase I Pre-clinical safety Early clinical safety Clinical Candidate Selection Entry Into Humans Phase IIa Phase IIb Phase III Proof of Concept Early clinical efficacy Key registration trials Entry Into Lifecycle Management pediatric plans submitted to EMA Full Dev. Decision FDA Registration Filing Decision for First Indication approval needed Dx development process and milestones Pre-clinical assay development ~2yrs Clinical Phase ~3yrs Replication Biomarker Discovery Confirm markers and reproducibility of assay Analytical Development Translation of assay onto a clinical platform BM Dx candidate identified BM assay on clinical platform Non-clinical testperformance Phase I Phase II Phase III Sensitivity & specificity PPV and NPV Clinical benefit and economics Clinical validation BM = Biomarker; EIH = Early In Humans; Rx = Therapeutic: Dx = Diagnostic; R&D = Research & Development Clinical utility Registration Clinical impact The costs of bringing new drugs to the market portfolio prioritization becomes crucial 1000 average costs of R&D per drug: 1 billion USD over 10 years patent expiry 800 market authorization 600 pediatric reward = 6 months additional exclusivity 400 Mio CHF Phase 3 “go” 200 0 -200 -400 -600 -800 Sales indication 1 Sales indication 2 Sales indication 3 COGs Total PP+FF Cum DCF COGs = Cost of Goods; DCF = Discounted Cash Flow Total R+D Only one success out of thirty-two candidates attrition rate, an additional challenge for pediatric• research Biologics success rate Benchmark on 14 pharmas – 4x > small molecules – but 8 mos longer cycle time • Therapeutic area success – low ~2% (NS) – high ~12% (virology) • Pediatric preclinical tasks – Juvenile toxicity = ~1 year – Formulation = ~18 months Challenges for portfolio selection – increase return on investment first-in-class, best-in-class – reduce costs of R&D – must have “early kills” Implications for academics – time & efforts invested ED: GLP Tox studies to start of phase 3 (5 yrs; 8% success) – no carry-on mechanisms LD: Start of phase 3 to market approval (3 yrs; 51% success) NMEs entries to achieve 1 approval: PC 32.4; P1 20.5; P2 9.6; P3 2.2; registration 1.3 – time to study start ED = Early Development; LD = Late Development; NME = New Molecular Entity; GLP = Good Laboratory Practices; PC = Pre Clinical; NS = neuroscience Defining “early planning” timing and outcome of Art. 7 PIP submissions PIP agreed unchanged or with minor modifications PIP agreed with major modifications PIP agreed with suggestion to come back for later discussion in a "Modification of agreed PIP" procedure PIP refused (negative PDCO opinion) PIP withdrawn 15% 18% 50% 2% 4% 47% 15% 12% 4% 4% 20% 40% 12% 58% 39% 24% 50% 31% 18% Before first human dose in adults End of Phase 1 in adults EFPIA/EMA Infoday - 23 May 2011 18% 19% Following confirmation Following completion of After starting paediatric of adult dose or proof of confirmatory clinical trials concept, but before the trials in adults, but start of paediatric trials before the start of paediatric trials Pediatric Drug Development in Pharma key success factors 1 Pediatric Expertise Leverage & support current internal pediatric expertise Portfolio Strategy 2 Assess scientific, medical and business opportunities with all drugs • consolidate past expertise into one cross-functional group • facilitate internal awareness training, develop best practices in pediatrics (ICF, template protocols) • “one shop stop, one pediatric voice” internally and externally • interface between early & late development • provide regulatory and pediatric expertise • liaise with academic groups, regulators, patient advocates, other pharma Early planning & execution 3 Ensure early pediatric evaluation of lead compounds & close interactions between early & late development teams Ensure access to patients 4 Optimize access to patients to ensure our societal role, inform clinical development plan and meet regulatory obligations • inform clinical development plan early on potential pediatric obligations & opportunities • ensure smooth transition between early (design) and late (execution) development teams • ensure unmet pediatric needs are addressed proactively • long-term commitment to pediatric cooperative groups: proactive, early interactions, co-development/partnerships, support to ISTs & educational programs • support innovative trial design Where pediatric opportunities defeat obligations explore the pediatric oncology strategic framework (2) MOLECULAR MAPPING & SCIENTIFIC OPPORTUNITY: Adequation to pediatric disease pathways (1) REGULATORY FIT: focus on drugs “at risk” (4) CLINICAL BARRIERS TO ENTRY: unmet medical needs vs. patient access (3) BUSINESS OPPORTUNITY: mid- and long-term potential Oncology drug opportunities All parties (industry, academics, regulators, parents) should meet regularly and agree on which drugs to prioritize within the existing oncology portfolio Prioritized pediatric oncology drug development Improve access to new drugs for children with high unmet medical needs innovative trial design to reduce timelines & optimize patient accrual Traditional early clinical trials in rare patient populations Drug A Drug B Drug C Additional clinical trials with Drug C years Continual reassessment method (adaptive trial design) Need to clarify Drug A Regulatory obligations Incentive Data protection Patent legislation Drug B Drug C Additional clinical trials with Drug C years Partnership between Pharma & Academia key success factors Academia Pharma Innovative ideas ++ ++ Great scientists ++ ++ Research facilities ++ ++ Manufacturing capacities ++ Direct patient access / network access ++ Medical expertise / disease-area expertise ++ Regulatory expertise / registration capacities Quality control & quality insurance ++ + Financial resources Independence + ++ ++ ++ + Partnership between Pharma & Academia evidence for complementarity Academia Pharma Innovative ideas ++ ++ Great scientists ++ ++ Research facilities ++ ++ Manufacturing capacities ++ Direct patient access / network access ++ Medical expertise / disease-area expertise ++ Regulatory expertise / registration capacities Quality control & quality insurance ++ + Financial resources Independence + ++ ++ ++ + Partnership between Pharma & Academia suggested improvements – a concerted effort • • • • Industry – provide as-early-as-reasonably-can access to new drugs to Academia, provide funding for preclinical testing – advocate internally and across industry for pediatric drug development – encourage cooperation between companies (pre competitive arena) – consider unmet medical needs in poor countries Academia – avoid off-label use once drug is approved in adults, encourage accrual in available pediatric trials – provide feasibility data through real-world epidemiology – improve accrual capacity through networking or consolidation of current structures – increase awareness of drug development with pediatric trainees, encourage internships Regulators – provide a regulatory pathway to allow for innovative trial designs (adaptive, combo, multicompany) – improve alignment between agencies (adolescent research), simplify procedures, rethink rewards Parents – advocate for randomized, controlled trials – keep all of us under pressure! Safety challenges in pediatric drug development long-term commitment to best serve children • children are not small adults: toxicity assessment in adults may not be predictive in children • monitoring for immediate toxicity is the norm but clearly insufficient for children exposed at an early age • under reporting / off-label use by pediatricians • long-term follow up is needed for safety outcomes – An ethical and moral obligation – A logistical challenge – A concerted effort for all parties involved • ongoing discussions between US and EU regulators, academic/cooperative groups and pharma • ultimately, will require physicians? patient/parents longterm commitment Regulators Parents Physicians Pharma Thank you rousseau.raphael@gene.com